Kosmetika onkologikoakimioterapiak eta erradioterapiak larruazalean eragindako efektu desiragaitzak eta horiek tratatzeko konposatu naturaletan oinarritutako formulazio berriak

  1. Miren Izaguirre
  2. Edorta Santos-Vizcaíno 1
  3. Aiala Salvador 1
  4. Amaia Esquisabel 1
  5. José Luis Pedraz 1
  6. Rosa María Hernández 1
  7. Manoli Igartua 1
  1. 1 NanoBioCel Taldea, EHU
Revista:
Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria

ISSN: 0214-9001

Año de publicación: 2018

Número: 33

Páginas: 35-53

Tipo: Artículo

DOI: 10.1387/EKAIA.17837 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria

Resumen

Often, cancer treatments create undesirable effects that may compromise the patient’s quality of life, given that besides killing cancer cells, they also destroy other healthy tissues. The present work discusses the skin diseases caused by cancer treatments, such as pruritus, flaking and/or ulceration in the most severe cases, as well as new products that are formulated to address these issues. With the aim of leaving aside the so far used corticoids, anti-histaminic drugs or lidocaine creams, dermo-cos-metic laboratories are now releasing alternative product lines for the skin treatment of patients with oncologic disorders. This is intended to improve their quality of life, hin-dering the unwanted late onset effects. By using plant extracts that have been used since ancient times, different formulations have been designed to promote the skin re-generation process. Product lines from laboratories such as Maria D’uol and OnCos-metics represent good examples of this. In other cases, besides plant origin compounds, other active molecules are also included. This is the case of BEACON Biomedicine laboratories, working with growth factors and a complex protein called Tectum 1; or IFC, where the fluids obtained from Cryptomphalus aspersa snails are used for the treatment of skin disorders caused by cancer.